Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, with the hiring of Debra Rock to lead the Company's Marketing Department, its internal commercial leadership team is complete.

Zomedica Completes Internal “Launch Team” for Upcoming TRUFORMA™ Commercialization

Zomedica (ZOM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zomedica (ZOM) Jumps: Stock Rises 5.5%

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Zomedica Corp. (NYSE:ZOM), so let's take a closer look at the sentiment that surrounds it in the current quarter.

Is Zomedica Corp. (ZOM) A Good Stock To Buy Now?

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) jumped 18.27% today. Here's an explanation of why that happened.

ZOM Stock Price Increases 18.27%: Why It Happened

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) has increased by 18.38% today. What caused the stock price to increase?

ZOM Stock Price: Explanation About The 18.38% Increase

We all want the best for our furry friends. That's why ZOM stock is surging higher on positive news from Zomedica Pharmaceuticals.

ZOM Stock News: Why Zomedica Pharmaceuticals Is Surging Today

Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine

Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™

ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”) today reported consolidated financial results for the third quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Zomedica Announces Third Quarter 2020 Financial Results

ANN ARBOR, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.

Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Special Virtual-Only Meeting

ANN ARBOR, Mich., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020.

Zomedica Announces Name Change

ANN ARBOR, Mich., Sept.  25, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”).

Zomedica Announces Shareholder Meeting Voting Results

ANN ARBOR, Mich., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders to be held on September 25, 2020. 

Zomedica Announces Letter to Shareholders in Connection With Annual  and Special Virtual-Only Meeting  

ANN ARBOR, Mich., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET.

Zomedica Announces Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference

Three new assays to be added to the five assays currently under development Three new assays to be added to the five assays currently under development

Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™

ANN ARBOR, Mich., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.

Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting

ANN ARBOR, Mich., Aug.  10, 2020  (GLOBE NEWSWIRE) --  Zomedica Pharmaceuticals Corp.  (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company, today reported consolidated financial results for the second quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Zomedica Announces Second Quarter 2020 Financial Results

ANN ARBOR, Mich., Aug.  07, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM), a veterinary health company, announced that Robert Cohen, Interim Chief Executive Officer, has been appointed to the Company's Board of Directors. Also appointed to the Board of Directors is Christopher Wolfenberg of the law firm Fasken Martineau DuMoulin LLP.

Zomedica Adds Two New Directors To Board Annual Meeting Materials Availability

Ideanomics Inc

Electrameccanica

Tonix Pharmaceuticals Hld

XpresSpa Group

Penny stocks will always be risky. That said, with the huge disconnect we're seeing in the markets, now may be a time to gamble.

The Top 8 Penny Stocks to Buy for August Uncertainty

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

Zomedica Pharmaceuticals Corp. (ZOM) closed the most recent trading day at $0.16, moving +0.57% from the previous trading session.

Zomedica Pharmaceuticals Corp. (ZOM) Gains But Lags Market: What You Should Know

ANN ARBOR, Mich., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (TSX-V: ZOM), a veterinary health company, announced that Shameze Rampertab has resigned as Chief Financial Officer and member of the Board of Directors, effective August 14, 2020.

Zomedica Announces Management Change

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a -0.3% move from the prior day.

Zomedica Pharmaceuticals Corp. (ZOM) Stock Sinks As Market Gains: What You Should Know

Permits Validation and Pilot Program Progress During COVID-19 Restrictions Permits Validation and Pilot Program Progress During COVID-19 Restrictions

Successful Remote Installation of TRUFORMA™

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a +1.31% move from the prior day.

Zomedica Pharmaceuticals Corp. (ZOM) Outpaces Stock Market Gains: What You Should Know

ANN ARBOR, Mich., July  07, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant.

News for Zomedica Stock (ZOM)